Läkemedelsakademin

Swedish Academy of Pharmaceutical Sciences

Dissolution Testing in Quality Control and Drug Development - from USP Vessels to Artificial Intelligence

October 20, 2020, Gothenburg, Sweden

Preliminary program

October 20

09.00	Registration with coffee/tea and sandwich
09.20	Introduction
09.30	Quality Control perspective – dissolution and disintegration methods and validation James Mann, AstraZeneca
10.05	Regulatory landscape of dissolution <i>To be decided</i>
10.40	Coffee/tea and exhibition
11.15	Equipment used for dissolution Jonas Johansson, AstraZeneca
11.50	Lunch
12.50	Bio relevant media Jennifer Dressmann, Goethe University
13.25	Dissolution – for in-vivo predictions Christer Tannergren
14.00	Efficacy – immediate (IR) and modified release (MR) Susanna Abrahamsén Alami, AstraZeneca
14.35	Coffee/tea with refreshments and exhibition
14.50	Dissolution testing – alternative administration routes e.g. inhalation and parenteral <i>Nikoletta Fotaki,</i> University of Bath, UK

15.25 **Increase bioavailability** *Christel Bergström*

- 16.00 **Dissolution test of generics to secure quality to patient** *Johan Breitholz,* AstraZeneca
- 16.35 Wrap -up